About Us

BELLUS Health is a clinical stage pharmaceutical company focused on developing a P2X3 antagonist to address various afferent hypersensitization-related disorders. The Company’s lead candidate, BLU-5937, is currently being studied in Phase 2 clinical trials in refractory chronic cough and chronic pruritus associated with atopic dermatitis.

We invite you to visit our investors’ relations page, including our Annual Information Form, to obtain more information about BELLUS Health.

View More

P2X3 Receptors and Chronic Cough

P2X3 receptors are ion channels expressed on sensory nerves throughout the body and play an important role in the sensitization to various stimuli.1  When P2X3 receptors become hypersensitized in the airways, it results in an exaggerated urge to cough.2 Bellus Heath is investigating the P2X3 antagonist, BLU-5937, as a potential treatment for refractory chronic cough.